Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer

BJU International

Volumn 108, Issue 9, 2011, Pages 1430-1438

  Tolonen, Teemu T ^a,b,d   Tammela, Teuvo L J ^c   Kujala, Paula M ^b   Tuominen, Vilppu J ^d   Isola, Jorma J ^d   Visakorpi, Tapio ^d  

^a VAASA CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Department of Urology ^*  (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

Author keywords

androgen deprivation; Gleason score; ISUP 2005; Ki 67; perineural invasion; prostate cancer

Indexed keywords

KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 7; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PERINEURIUM; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CELL CYCLE PROTEINS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80055018711     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10253.x     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, et al,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
2. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
3. Lu-Yao GL, Albertsen PC, Moore DF, et al,. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-81 (Pubitemid 351969301)
4. Palmberg C, Koivisto P, Visakorpi T, Tammela TL,. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol 1999; 36: 191-6 (Pubitemid 29381303)
5. De Dosso S, Berthold DR,. Docetaxel in the management of prostate cancer: current standard of care and future directions. Expert Opin Pharmacother 2008; 9: 1969-79
6. Walz J, Chun FKH, Klien EA, et al,. Nomogram for predicting the probability of early recurrence after radical prostatectomy for Prostate Cancer. J Urol 2009; 181: 601-8
7. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499-507 (Pubitemid 29220858)
8. Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG,. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 2002; 59: 740-5 (Pubitemid 34461987)
9. Stephenson AJ, Scardino PT, Eastham JA, et al,. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005-12
10. Makarov DV, Trock BJ, Humphreys EB, et al,. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-101 (Pubitemid 46891611)
11. San Francisco IF, Regan MM, Olumi AF, DeWolf WC,. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol 2004; 171: 1492-9 (Pubitemid 38365404)
12. Villamon-Fort R, Martinez-Jabaloyas JM, Soriano-Sarria P, et al,. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy. Urol Int 2007; 78: 328-33 (Pubitemid 46725704)
13. Loeb S, Epstein JI, Humphrey EB, Walsh PC,. Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes? BJU Int 2009; 105: 1510-3
14. Zellweger T, Gunther S, Zlobec I, et al,. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 2009; 124: 2116-23
15. Bubendorf L, Tapia C, Gasser TC, et al,. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998; 29: 949-54 (Pubitemid 28422042)
16. Pollack A, DeSilvio M, Khor LY, et al,. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004; 22: 2133-40 (Pubitemid 41095146)
17. Gunia S, Albrecht K, Koch S, et al,. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 2008; 26: 243-50
18. Laurila M, Tammela TL, Auvinen A, et al,. Biological aggressiveness of prostate cancer in the Finnish screening trial. Int J Cancer 2009; 124: 547-52
19. Simon JA, Lange CA,. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-9
20. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA,. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95: 661-8 (Pubitemid 36603722)
21. Varambally S, Dhanasekaran SM, Zhou M, et al,. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9
22. Kidani K, Osaki M, Tamura T, et al,. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009; 45: 39-46
23. Matsukawa Y, Semba S, Kato H, et al,. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006; 97: 484-91 (Pubitemid 43811589)
24. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T,. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006; 45: 639-45 (Pubitemid 43727151)
25. Laitinen S, Martikainen PM, Tolonen T, et al,. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595-602 (Pubitemid 350308951)
26. Shi YK, Yu YP, Zhu ZH, et al,. MCM7 interacts with androgen receptor. Am J Pathol 2008; 173: 1758-67
27. Ren B, Yu G, Tseng GC, et al,. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006; 25: 1090-8 (Pubitemid 43277016)
28. Scher HI, Halabi S, Tannock I, et al,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59
29. Tuominen V, Isola J,. The application of JPEG2000 in virtual microscopy. J Digit Imaging 2009; 22: 250-8
30. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42 (Pubitemid 41232997)
31. Collins TJ,. ImageJ for microscopy. Biotechniques 2007; 43 (1 Suppl.): 25-30
32. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J,. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010; 12: R56
33. Ruifrok AC, Johnston DA,. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001; 23: 291-9 (Pubitemid 32762920)
34. Graff JN, Mori M, Li H, et al,. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. J Urol 2007; 177: 1307-12 (Pubitemid 46436011)
35. Smaletz O, Scher HI, Small EJ, et al,. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-82
36. Cooperberg MR, Hinotsu S, Namiki M, et al,. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009; 27: 4306-13
37. Stark JR, Perner S, Stampfer MJ, et al,. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27: 3459-64
38. Makarov DV, Sanderson H, Partin AW, Epstein JI,. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 2002; 167: 2440-2 (Pubitemid 34533141)
39. Fanning DM, Kay E, Fan Y, Fitzpatrick JM, Watson RW,. Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade. BJU Int 2010; 105: 631-5
40. Allsbrook WC Jr, Mangold KA, Johnson MH, et al,. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001; 32: 74-80 (Pubitemid 32150631)
41. Allsbrook WC Jr, Mangold KA, Johnson MH, et al,. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001; 32: 81-8 (Pubitemid 32150632)
42. Billis A, Guimaraes MS, Freitas LL, et al,. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol 2008; 180: 548-52
43. Helpap B, Egevad L,. Modified Gleason grading. An updated review. Histol Histopathol 2009; 24: 661-6
44. Lotan TL, Epstein JI,. Clinical applications of changing definitions within the Gleason grading system. Nat Rev Urol 2010; 7: 136-42
45. Thompson IM, Canby-Hagino E, Lucia MS,. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst 2005; 97: 1236-7
46. Helpap B, Egevad L,. Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy. Anal Quant Cytol Histol 2008; 30: 1-7 (Pubitemid 351312094)
47. Winkler MH, Khan FA, Kulinskaya E, et al,. The total percentage of biopsy cores with cancer improves the prediction of pathological stage after radical prostatectomy. BJU Int 2004; 94: 812-5 (Pubitemid 39472475)
48. Moussa AS, Li J, Soriano M, et al,. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 2009; 103: 43-8
49. Merrilees AD, Bethwaite PB, Russell GL, Robinson RG, Delahunt B,. Parameters of perineural invasion in radical prostatectomy specimens lack prognostic significance. Mod Pathol 2008; 21: 1095-100
50. Yu HH, Song DY, Tsai YY, et al,. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. Urology 2007; 70: 111-6 (Pubitemid 47081097)
51. Maru N, Ohori M, Kattan MW, Scardino PT, Wheeler TM,. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol 2001; 32: 828-33 (Pubitemid 32803984)
52. Visakorpi T, Kallioniemi OP, Paronen IY, et al,. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. Br J Cancer 1991; 64: 578-82
53. Matsuura H, Hayashi N, Kawamura J, Shiraishi T, Yatani R,. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation. Eur Urol 2000; 37: 212-7 (Pubitemid 30103075)
54. Albertsen PC, Hantey JA, Penson DF, Barrows G, Fine J,. 13-Year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 2007; 177: 932-6 (Pubitemid 46223573)
55. Lee N, Fawaaz R, Olsson CA, et al,. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000; 48: 1443-6